Cantargia Croissance future

Future contrôle des critères 2/6

Les bénéfices de Cantargia devraient diminuer de 3.4% par an tandis que son chiffre d'affaires annuel devrait croître de 50.1% par an. Le BPA devrait croître de en baisse de 21.2% par an.

Informations clés

-3.4%

Taux de croissance des bénéfices

-21.2%

Taux de croissance du BPA

Biotechs croissance des bénéfices	45.7%
Taux de croissance des recettes	50.1%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

Prévisions de croissance des bénéfices et des revenus

OM:CANTA - Estimations futures des analystes et données financières antérieures (SEK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	18	-229	-163	-148	3
12/31/2025	194	-36	-147	69	3
12/31/2024	N/A	-166	-207	-187	3
9/30/2024	N/A	-194	-193	-193	N/A
6/30/2024	N/A	-228	-234	-234	N/A
3/31/2024	N/A	-241	-267	-267	N/A
12/31/2023	N/A	-280	-287	-287	N/A
9/30/2023	N/A	-299	-299	-292	N/A
6/30/2023	N/A	-293	-295	-287	N/A
3/31/2023	N/A	-330	-320	-313	N/A
12/31/2022	N/A	-372	-366	-359	N/A
9/30/2022	N/A	-385	-387	-387	N/A
6/30/2022	N/A	-419	-419	-419	N/A
3/31/2022	N/A	-411	-406	-406	N/A
12/31/2021	N/A	-367	-347	-346	N/A
9/30/2021	N/A	-319	-302	-301	N/A
6/30/2021	N/A	-255	-231	-230	N/A
3/31/2021	N/A	-206	-187	-186	N/A
12/31/2020	N/A	-173	-165	-156	N/A
9/30/2020	N/A	-153	-165	-149	N/A
6/30/2020	N/A	-139	-151	-135	N/A
3/31/2020	N/A	-127	-144	-129	N/A
12/31/2019	N/A	-111	-118	-111	N/A
9/30/2019	N/A	-102	-97	-97	N/A
6/30/2019	N/A	-98	-92	-92	N/A
3/31/2019	N/A	-101	-88	-88	N/A
12/31/2018	N/A	-91	-105	-105	N/A
9/30/2018	N/A	-78	-72	-72	N/A
6/30/2018	N/A	-68	N/A	-65	N/A
3/31/2018	N/A	-56	N/A	-54	N/A
12/31/2017	N/A	-60	N/A	-41	N/A
9/30/2017	N/A	-65	N/A	-69	N/A
6/30/2017	N/A	-66	N/A	-64	N/A
3/31/2017	N/A	-58	N/A	-54	N/A
12/31/2016	N/A	-47	N/A	-42	N/A
9/30/2016	N/A	-34	N/A	-26	N/A
6/30/2016	N/A	-24	N/A	-21	N/A
3/31/2016	N/A	-22	N/A	-19	N/A
12/31/2015	N/A	-17	N/A	-30	N/A
9/30/2015	N/A	-15	N/A	-35	N/A
6/30/2015	N/A	-14	N/A	-13	N/A
3/31/2015	N/A	-10	N/A	-10	N/A
12/31/2014	N/A	-8	N/A	7	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CANTA devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CANTA devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CANTA devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CANTA ( 50.1% par an) devrait croître plus rapidement que le marché Swedish ( -0% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CANTA ( 50.1% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CANTA devrait être élevé dans 3 ans

Cantargia Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 24% to kr9.67

Forecast to breakeven in 2026

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

No longer forecast to breakeven

Price target decreased to kr22.00

Recent updates

Price target decreased by 24% to kr9.67

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

New major risk - Share price stability

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Can Cantargia (STO:CANTA) Afford To Invest In Growth?

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Price target decreased to kr22.00

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy